Welcome!

News Feed Item

Cancer Monoclonal Antibody Partnering Terms and Agreements



 

 

 

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 350 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract
.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since January 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus, and monoclonal antibody technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.


Report scope

Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.


Cancer Monoclonal Antibody Partnering Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 300 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2009


In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to available deals and contract documents for over 300 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary


Chapter 1 – Introduction

Chapter 2 – Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates

Chapter 3 – Leading cancer monoclonal antibody deals

3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value

Chapter 4 – Big pharma cancer monoclonal antibody deals

4.1. Introduction

4.2. How to use big pharma partnering deals

4.3. Big pharma cancer monoclonal antibody partnering company profiles

Abbott
Abbvie
Actavis (formerly called Watson)
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 – Big biotech cancer monoclonal antibody deals

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech cancer monoclonal antibody partnering company profiles

Emergent BioSolutions
Genmab
LFB Group
Morphosys
PDL BioPharma
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum

Chapter 6 – Cancer monoclonal antibody dealmaking directory

6.1. Introduction

6.2. Company A-Z

6.3. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.4. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

6.5. By oncology therapy area

Oncology
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Solid tumors
Cancer pain
Thyroid cancer
6.6. By monoclonal antibody type
Chapter 7 –Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Upgrades for subscription access products
Order Form – Therapy Reports
Order Form – Technology Reports

Table of figures

Figure 1: Cancer monoclonal antibody partnering since 2009
Figure 2: Big pharma – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 6: Active cancer monoclonal antibody dealmaking activity– 2009 to 2014
Figure 7: Cancer monoclonal antibody partnering by deal type since 2009
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by type since 2009
Figure 11: Cancer monoclonal antibody deals with a headline value – by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million – discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million – preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million – phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million – phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million – phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million – regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million – marketed stage
Figure 19: Cancer monoclonal antibody deal headline value – median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values – by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million – discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million – preclinical stage
Figure 23: Cancer monoclonal antibody deal upfront value distribution, US$million – phase I stage
Figure 24: Cancer monoclonal antibody deal upfront value distribution, US$million – phase II stage
Figure 25: Cancer monoclonal antibody deal upfront value distribution, US$million – phase III stage
Figure 26: Cancer monoclonal antibody deal upfront value distribution, US$million – regulatory stage
Figure 27: Cancer monoclonal antibody deal upfront value distribution, US$million – marketed stage
Figure 28: Cancer monoclonal antibody deal upfront value – median value by stage of development
Figure 29: Cancer monoclonal antibody deals with milestone payment – by stage of development
Figure 30: Cancer monoclonal antibody deal milestone distribution, US$million – discovery stage
Figure 31: Cancer monoclonal antibody deal milestone value distribution, US$million – preclinical stage
Figure 32: Cancer monoclonal antibody deal milestone value distribution, US$million – phase I stage
Figure 33: Cancer monoclonal antibody deal milestone value distribution, US$million – phase II stage
Figure 34: Cancer monoclonal antibody deal milestone value distribution, US$million – phase III stage
Figure 35: Cancer monoclonal antibody deal milestone value distribution, US$million – regulatory stage
Figure 36: Cancer monoclonal antibody deal milestone value distribution, US$million – marketed stage
Figure 37: Cancer monoclonal antibody deals with royalty rates
Figure 38: Cancer monoclonal antibody deal royalty rate distribution, US$million – discovery stage
Figure 39: Cancer monoclonal antibody deal royalty rate value distribution, US$million – preclinical stage
Figure 40: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase I stage
Figure 41: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase II stage
Figure 42: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase III stage
Figure 43: Cancer monoclonal antibody deal royalty rate value distribution, US$million – regulatory stage
Figure 44: Cance monoclonal antibody deal royalty rate value distribution, US$million – marketed stage
Figure 45: Cancer monoclonal antibody deal royalty value – median value by stage of development
Figure 46: Top cancer monoclonal antibody deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions
Figure 50: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets



Read the full report:
Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.